Esperion Therapeutics Inc (NASDAQ: ESPR) is 1.82% higher on its value in year-to-date trading and has touched a low of $1.58 and a high of $3.94 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ESPR stock was last observed hovering at around $2.28 in the last trading session, with the day’s loss setting it -0.04%.
Currently trading at $2.24, the stock is 0.01% and -8.47% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.33 million and changing -1.75% at the moment leaves the stock 0.19% off its SMA200. ESPR registered -25.33% loss for a year compared to 6-month gain of -10.40%. The firm has a 50-day simple moving average (SMA 50) of $2.445 and a 200-day simple moving average (SMA200) of $2.23765.
The stock witnessed a -16.73% loss in the last 1 month and extending the period to 3 months gives it a 13.71%, and is 4.19% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.63% over the week and 7.68% over the month.
Esperion Therapeutics Inc (ESPR) has around 240 employees, a market worth around $441.36M and $295.45M in sales. Profit margin for the company is -29.37%. Distance from 52-week low is 41.77% and -43.15% from its 52-week high. The company has generated returns on investments over the last 12 months (-58.53%).
with sales reaching $63.06M over the same period.The EPS is expected to grow by 85.06% this year, but quarterly earnings will post 180.41% year-over-year. Quarterly sales are estimated to grow 95.53% in year-over-year returns.
Esperion Therapeutics Inc (ESPR) Top Institutional Holders
222.0 institutions hold shares in Esperion Therapeutics Inc (ESPR), with institutional investors hold 66.31% of the company’s shares. The shares outstanding are 195.44M, and float is at 195.08M with Short Float at 16.58%. Institutions hold 65.99% of the Float.
The top institutional shareholder in the company is WASATCH ADVISORS LP with over 16.86 million shares valued at $37.44 million. The investor’s holdings represent 9.9628% of the ESPR Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 13.98 million shares valued at $31.04 million to account for 8.2617 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 10.82 million shares representing 6.3907% and valued at over $24.01 million, while BELLEVUE GROUP AG holds 5.8751 of the shares totaling 9.94 million with a market value of $22.08 million.
Esperion Therapeutics Inc (ESPR) Insider Activity
The most recent transaction is an insider sale by Halladay Benjamin, the company’s Chief Financial Officer. SEC filings show that Halladay Benjamin sold 3,245 shares of the company’s common stock on Dec 17 ’24 at a price of $2.42 per share for a total of $7866.0. Following the sale, the insider now owns 0.24 million shares.
Esperion Therapeutics Inc disclosed in a document filed with the SEC on Dec 17 ’24 that Warren Eric (Chief Commercial Officer) sold a total of 2,234 shares of the company’s common stock. The trade occurred on Dec 17 ’24 and was made at $2.43 per share for $5426.0. Following the transaction, the insider now directly holds 0.16 million shares of the ESPR stock.
Still, SEC filings show that on Dec 17 ’24, Koenig Sheldon L. (President and CEO) disposed off 12,447 shares at an average price of $2.47 for $30694.0. The insider now directly holds 739,819 shares of Esperion Therapeutics Inc (ESPR).
